Skip to main content

Table 2 Demographic and clinical characteristics of the study population

From: Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma

 

SNEA group patients

AA group patients

Healthy subjects

Number, n

8

12

12

Sex, M/F

1/7

7/5

3/9

Age, years

52.0*# ± 4.2

26.0 ± 2.4

29.0 ± 2.2

BMI, kg/m2

25.5 ± 1.9

25.1 ± 1.8

22.5 ± 1.5

FEV1, l

1.5 ± 0.2*#

4.0 ± 0.2

3.9 ± 0.2

FEV1, % of predicted

56.6 ± 7.2*#

94.6 ± 3.8

103.8 ± 2.7

PD20, mean (range), mg (n) γ

ND

0.11 ± 0.02

NR

Blood eosinophil count, × 109/l

0.71 ± 0.17*#

0.33 ± 0.06#

0.20 ± 0.02

FeNO, ppb

59.3 ± 10.1*#

57.6 ± 5.5#

14.3 ± 1.4

IgE, IU/ml

128.3 ± 30.2*#

174.3 ± 26.5#

33.0 ± 7.1

  1. AA Allergic asthma, SNEA Severe non-allergic eosinophilic asthma, F Female, M Male, FEV1 Forced expiratory volume in 1 s, PD20 The provocation dose of methacholine causing a 20% decrease in FEV1, FeNO Fractional exhaled nitric oxide, IgE Immunoglobulin E, ND Not done, NR Not responded
  2. Data presented as the mean ± standard error of the mean
  3. γairway responsiveness was tested for 10 AA subjects; 1 subject had positive bronchial reversibility test
  4. *p < 0.01 comparing with AA group
  5. #p < 0.01 comparing with HS group